17 September, 2017
The closing price represents the final price that a stock is traded for on a trading day. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Epizyme, Inc. (NASDAQ:EPZM) have caught the attention of investors.
Company chares are trading at $16.05 which is marginally higher than the 50 day moving average which is $14.97 and which is just a bit higher than the 200 day moving average of $15.15. Trading was light with 403K shares changing hands by the end of trading on Thursday. (EPZM) is its Earnings per Share or EPS. Epizyme, Inc. The stock's market cap is $932.53 million.
The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $7.15B. Next quarter's EPS is forecasted to be $-0.70 and the next full year EPS is projected to be $-2.50. The business had revenue of $10.00 million for the quarter, compared to analysts' expectations of $3.95 million. EPS breaks down the profitability of the company on a single share basis. During the same period in the previous year, the business earned ($0.49) earnings per share.
In the latest earnings report the EPS was $-2.07 and is projected to be $-2.39 for the current year with 58,466,000 shares now outstanding.
The legal version of this story can be read at https://weekherald.com/2017/09/13/peter-tai-ching-ho-sells-15000-shares-of-epizyme-inc-epzm-stock.html. If you are reading this story on another site, it was illegally copied and republished in violation of USA & global trademark and copyright legislation. Equity research analysts have given opinions on where they foresees the stock level. ValuEngine upgraded Epizyme from a "sell" rating to a "hold" rating in a research report on Saturday, June 24th. Leerink Swann reiterated an "outperform" rating and issued a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Zacks Investment Research downgraded Epizyme from a "buy" rating to a "hold" rating in a research report on Tuesday, January 17th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Epizyme in a research report on Sunday, November 6th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions. Deerfield Management Co. boosted its stake in Epizyme by 449.9% in the fourth quarter. Dimensional Fund Advisors LP boosted its position in Epizyme by 61.4% during the 1st quarter.
Presently Epizyme, Inc. (NASDAQ:EPZM) stock have an ABR of 1.14. Palo Alto Investors LLC boosted its stake in Epizyme by 7.9% in the fourth quarter. Insider ownership decreased by a total of 48024 shares, which suggests that EPZM's key executives are feeling less optimistic about the outlook for the stock. Finally, Woodstock Corp boosted its position in Epizyme by 5.5% during the 2nd quarter. Short shares increased from 6,147,417 to 6,493,690 over that period.
